AI assistant
INVION LIMITED — Major Shareholding Notification 2020
Dec 3, 2020
65148_rns_2020-12-03_eb213d20-2d43-4305-b8ee-9b8a66d249f6.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer
ASX ANNOUNCEMENT
==> picture [145 x 53] intentionally omitted <==
DISTRIBUTION OF SHARES BY SUBSTANTIAL SHAREHOLDER
MELBOURNE (AUSTRALIA) 4 December 2020: Invion Limited (ASX: IVX) ( Invion ) has been advised by Unlimited Innovation Group Limited ( UIG ), the company’s largest shareholder holding 50.8% of Invion’s shares, that UIG has completed an in-specie distribution of the Invion shares held by it to the members of UIG.
Invion has further been informed by UIG that, to ensure the distribution of shares by UIG to its members occurs in an orderly manner, the UIG members have agreed with UIG to enter into voluntary escrow arrangements ranging between 3 to 12 months, a summary of which is provided below.
| provided below. | |||
|---|---|---|---|
| Description | Escrow expiry | Quantity of securities | No. of holders |
| IVX 3 months escrow | 01/03/2021 | 1,432,841,408 | 16 holders |
| shares till 01/03/2021 | |||
| (IVXESC0321) | |||
| IVX 6 months escrow | 01/06/2021 | 1,160,779,413 | 32 holders |
| shares till 01/06/2021 | |||
| (IVXESC0621) | |||
| IVX 12 months escrow | 01/12/2021 | 220,682,156 | 1 holder |
| shares till 01/12/2021 | |||
| (IVXESC1221) |
Invion is not a party to the escrow arrangements but UIG has provided assurances to Invion's board that it will enforce these arrangements.
A current statement setting out the names of the 20 largest shareholders of fully paid ordinary shares and the percentage held by each is attached.
This announcement is authorised by the Board of Invion.
Investor and Media enquiries:
Thian Chew (Chairman) T: +61 3 9692 7222 E: [email protected]
Brendon Lau (Investor & Media Relations) T: +61 409 341 613 E: [email protected]
Invion Limited ABN 76 094 730 417
Level 4, 100 Albert Road, South Melbourne, VIC, 3205, Australia P: +61 9692 7222 W: www.inviongroup.com
ASX ANNOUNCEMENT
==> picture [145 x 53] intentionally omitted <==
INVION LIMITED
Top holders
==> picture [452 x 286] intentionally omitted <==
----- Start of picture text ----- Security: ORD.ASX [ORDINARY + ESCROW ORDINARY]Top holders: 20Rank Name A/C designation 02 Dec 2020 %IC1 POLAR VENTURES LIMITED 545,217,721 9.862 NGPDT GREATER CHINA LIMITED 545,152,297 9.863 MR HONSUE CHO 284,626,482 5.154 ACSLNC PTY LTD ACSLNC FAMILY 267,250,000 4.835 RMWC PTY LTD RMWC FAMILY 220,682,156 3.996 YONG CHEN 200,000,000 3.627 BNP PARIBAS NOMINEES PTY LTD 156,489,665 2.838 HONG DENG 141,739,597 2.569 SHENGLI WANG 136,288,074 2.4610 GRAEME ERIC SCOTT 118,750,000 2.1511 MING KIT HUI 96,666,667 1.7512 RMWC PTY LTD <RMWC FAMILY A/C> 93,865,000 1.7013 SHUBO MIAO 73,333,333 1.3314 SHENGWEI OU 66,666,667 1.2114 MAK SIEW WEI 66,666,667 1.2115 EQ INVESTMENT PTY LTD 62,500,000 1.1316 PLATINUM HOMES LTD 62,333,333 1.1317 SOO CORP PTY LTD 56,666,666 1.0218 YINGHUA MA 54,000,000 0.9819 HONGHUI CHEN 52,786,440 0.9520 CITICORP NOMINEES PTY LIMITED 47,746,624 0.86Total 3,349,427,389 60.58Balance of register 2,179,614,906 39.42Grand total 5,529,042,295 100.00----- End of picture text -----
About Invion
Invion is a life-science company that is leading the global research and development of PhotosoftTM technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the PhotosoftTM technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). This announcement was approved for release by the Board of Invion Limited. For further information please contact [email protected].
About Photodynamic Therapy (PDT)
Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.
Invion Limited ABN 76 094 730 417
Level 4, 100 Albert Road, South Melbourne, VIC, 3205, Australia
P: +61 9692 7222 W: www.inviongroup.com